SEARCH

SEARCH BY CITATION

References

  • 1
    Gall S, Bundy B, Beecham J, Whitney C, Homesley H, Lifshitz S, et al. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum (a Gynecologic Oncology Group study). Gynecol Oncol 1986; 25: 2636.
  • 2
    Creasman W, Gall S, Bundy B, Beecham J, Mortel R, Homesley H. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study). Gynecol Oncol 1989; 35: 37882.
  • 3
    Omura G, Bundy B, Berek J, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 45765.
  • 4
    Omura G, Morrow P, Blessing J, Miller A, Buchsbaum H, Homesley H, et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51: 783–9.
  • 5
    Omura G, Blessing J, Ehrlich C, Miller A, Yordan E, Creasman W, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma (a Gynecologic Oncology Group study). Cancer 1986; 57: 172530.
  • 6
    Omura G, Brady M, Homesley H, Yordan E, Major F, Buchsbaum H, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 113850.
  • 7
    Creasman W, Omura G, Brady M, Yordan E, DiSaia P, Beecham J. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 39: 23943.
  • 8
    McGuire W, Hoskins W, Brady M, Homesley H, Clarke-Pearson D. A phase III trial of dose intense versus standard dose cisplatin plus cytoxan in advanced ovarian cancer. Presented at the Third Biennial Meeting of the International Gynecologic Cancer Society, Cairns, Australia, September 22–26, 1991.
  • 9
    Scheffé H. The analysis of variance. New York: John Wiley & Sons, 1959.
  • 10
    Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952; 47: 583621.
  • 11
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 12
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 16370.